News & Events

RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies

Seattle, WA, June 1, 2021 – RareCyte announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients. The Synaptophysin Panel Kit was validated to meet clinical standards and enables blood-based investigation of a prominent mechanism by which tumors become resistant to second-line endocrine therapies.

“Resistance to second-line anti-androgen therapies has emerged as an important clinical challenge,” explained Eric Kaldjian, MD, Chief Medical Officer of RareCyte. “Identification of synaptophysin on CTCs via a blood sample will allow non-invasive monitoring for neuroendocrine transformation in clinical trials and has the potential to provide diagnostic confirmation when it is suspected clinically.”

The assay comprises processing blood to slides with the AccuCyte® Sample Preparation System followed by staining with the RarePlex® 0920-VB Synaptophysin CTC Panel Kit and imaging on a CyteFinder® Instrument.

“Synaptophysin is a well-recognized neuroendocrine marker, so analyzing synaptophysin expression on CTCs may yield new insights about the neuroendocrine phenotype in prostate cancer and other malignancies” states Amir Goldkorn, MD, an oncologist at University of Southern California (USC) Norris Cancer Center and associate professor of medicine at Keck School of Medicine of USC.

The Synaptophysin CTC Panel Kit is now available for purchase; more information on the kit and the RareCyte platform is available at

About RareCyte, Inc.

RareCyte offers Precision Biology solutions focused on multiplexed analysis of cells and tissue with applications in life science research and clinical diagnostics. The company has deep experience in developing advanced precision systems and consumables used in cutting-edge labs worldwide. Our customers perform innovative research, bring new therapeutic and diagnostic assays to market, and perform a wide range of single cell applications in oncology and disease research.

For Research Use Only. Not for use in diagnostic procedures.

Media Contact: